| Literature DB >> 22919300 |
Germana Beha1, Giuseppe Sarli, Barbara Brunetti, Francesco Sassi, Domenico Ferrara, Cinzia Benazzi.
Abstract
Myoepithelium is present in canine mammary tumors as resting and proliferative suprabasal and spindle and stellate interstitial cells. The aim of this paper was to evaluate a panel of markers for the identification of four different myoepithelial cell morphological types in the normal and neoplastic mammary gland and to investigate immunohistochemical changes from an epithelial to a mesenchymal phenotype. Cytokeratin 19 (CK19), cytokeratin 5/6 (CK5/6), cytokeratin 14 (CK14), estrogen receptor (ER), p63 protein, vimentin (VIM), and α-smooth muscle actin (Alpha-SMA) antibodies were used on 29 neoplasms (3 benign and 3 malignant myoepithelial tumors, 7 carcinomas in benign-mixed tumors and 16 complex carcinomas) and on normal tissue of mammary glands. All these antibodies were also tested on 3 mammary tissues from animals with no mammary pathology. The myoepithelial markers were well expressed in the suprabasal cells and gradually lost in the motile types, with the stellate cells maintaining only VIM expression typical of mesenchyma. ER labeled some resting and motile myoepithelial cells. On the basis of our results, we propose a transition from myoepithelial immotile cells into migratory fibroblast-like cells. This transition and the characterization of an immunohistochemical panel for resting and motile myoepithelial cells shed more light on the biological behavior of myoepithelial cells.Entities:
Mesh:
Year: 2012 PMID: 22919300 PMCID: PMC3420080 DOI: 10.1100/2012/252034
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Primary antibodies, resources, and dilutions used in immunohistochemistry.
| Antibody (anti-) | Clone | Manufacturer | Dilution |
|---|---|---|---|
| P63 | 4A4 | Dako (Glostrup, Denmark) | 1 : 50 |
| Alpha-SMA | 1A4 | Dako (Glostrup, Denmark) | 1 : 100 |
| Cytokeratin 19 | BA17 | Dako (Glostrup, Denmark) | 1 : 50 |
| Cytokeratin 14 | Ab-1 (LL002) | NeoMarkers (Fremont, CA, USA) | 1 : 300 |
| Cytokeratins 5/6 | D5/16B4 | Zymed (South San Francisco, CA, USA) | 1 : 100 |
| VIM | V9 | Dako (Glostrup, Denmark) | 1 : 100 |
| ER | 1D5 | Dako (Glostrup, Denmark) | 1 : 25 |
Figure 1Suprabasal myoepithelial cells: resting (thin arrows) and proliferative (thick arrows) cells. Immunohistochemical expression of a panel of antibodies applied by IHC, 63x (a) Hematoxylin-eosin; (b) anti-CK19 antibodies labeling the cytoplasm; (c) anti-ER antibodies labeling the nuclei; (d) anti-CK 5/6 antibodies labeling the cytoplasm; (e) anti-CK14 antibodies labeling the cytoplasm; (f) anti-VIM antibodies labeling the cytoplasm; (g) anti-Alpha-SMA antibodies labeling the cytoplasmic membrane; (h) anti-p63 antibodies labeling the nuclei.
Figure 2Motile myoepithelial cells: spindle (asterisks) and stellate (stars) cells. Immunohistochemical expression of a panel of antibodies applied by IHC. 63x (a) Hematoxylin-eosin; (b) anti-CK19 antibodies labeling the cytoplasm; (c) anti-ER antibodies labeling the nuclei; (d) anti-CK 5/6 antibodies labeling the cytoplasm; (e) anti-CK14 antibodies labeling the cytoplasm; (f) anti-VIM antibodies labeling the cytoplasm; (g) anti-Alpha-SMA antibodies labeling the cytoplasmic membrane; (h) anti-p63 antibodies labeling the nuclei.
Immunohistochemical results for suprabasal and motile myoepithelial cells.
| Type of lesion | Cell morphology | Antibodies for∗ | |||||||
|---|---|---|---|---|---|---|---|---|---|
| p63 | CK14 | CK5/6 | CK19 | Alpha-SMA | VIM | ER | |||
| Normal mammary gland ( | Suprabasal | resting | ++ | ++ | + | − | ++ | ++ | + |
| proliferative | ++ | + | + | − | ++ | ++ | + | ||
|
| |||||||||
| Mammary tissue in the same tumor line ( | Suprabasal | resting | ++ | ++ | ++ | − | ++ | ++ | +(12/29) |
| proliferative | ++ | + | + | − | ++ | ++ | +(12/29) | ||
|
| |||||||||
| Benign myoepithelioma ( | Motile | spindle | − | ±(2/3) | − | − | − | ++ | − |
| stellate | − | − | − | − | − | ++ | − | ||
|
| |||||||||
| Malignant myoepithelioma ( | Motile | spindle | − | ± | − | − | − | ++ | − |
| stellate | − | − | − | − | − | ++ | − | ||
|
| |||||||||
| Carcinoma in benign-mixed tumor ( | Suprabasal | resting | ++ | ++ | +(5/7) | − | ++ | ++ | +(4/7) |
| proliferative | ++ | +/±(2/7) | +(3/7) | − | ++ | ++ | +(4/7) | ||
| Motile | spindle | − | ±(2/7) | +(3/7) | − | ±(5/7) | ++ | +(3/7) | |
| stellate | − | − | − | − | − | ++ | +(3/7) | ||
|
| |||||||||
| Complex carcinoma ( | Suprabasal | resting | ++ | ++(15/16) | +(11/16) | − | ++ | ++ | +(7/16) |
| proliferative | ++ | +(15/16) | +(7/16) | − | ++ | ++ | +(7/16) | ||
| Motile | spindle | − | ±(2/16) | +(7/16) | − | ±(5/16) | ++ | +(6/16) | |
| stellate | − | − | − | − | ±(2/16) | ++ | +(6/16) | ||
∗−: no stained cells; ±: less than 5% positive cells; +: 5–50% positive cells; ++: more than 50% positive cells.
°: the motile phonotype is not updated because not present.
§: the suprabasal phonotype is not updated because not detectable around luminal cells.